Abstract
Harnessing the body’s own immune system to fight cancer is one of the most encouraging fields of cancer research today. Promising new cancer immunotherapies are currently being tested in preclinical and clinical trials, and a few have also reached regulatory approval. Likewise, the immunological properties of conventional therapies are being rediscovered and reinvestigated. It is now clear that the immune system is involved in antitumor action of most antitumor therapies. Special attention has been on different local ablative techniques, electrochemotherapy (ECT) being one of them. The main proposed mechanism of immunological involvement in the effectiveness of these therapies is their ability to induce an immunogenic form of cell death characterized by the release of tumor antigens from the therapy-killed cells in the context of a “danger signal,” which can lead to formation of immune response against the released tumor antigens. Hence, ECT can be seen as an in situ vaccine. But since no systemic antitumor effects have been reported after ECT in clinical practice so far, this means that ECT monotherapy is not sufficient to overcome the tumor-tolerating immunosuppressive microenvironment of the tumor. Therefore, combining ECT with immunotherapy could be an efficient way to cure both the ECT-treated nodules and any distant nodule. In this chapter, the hypothesis of ECT as in situ vaccine will be present, putative adjuvants that could be, or already were, tested in combination with ECT will be listed, and the first clinical data for different combinations of ECT and immunotherapy that support the concept will be presented.
This is a preview of subscription content, log in via an institution to check access.
References
Andersen MH, Gehl J, Reker S, Pedersen LO, Becker JC, Geertsen P, Straten PT (2003) Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administration. Semin Cancer Biol 13:449–459
Becker JC, Andersen MH, Schrama D, Thor Straten P (2013) Immune-suppressive properties of the tumor microenvironment. Cancer Immunol Immunother 62:1137–1148
Blank CU, Haanen JB, Ribas A, Schumacher TN (2016) Cancer immunology. The “cancer immunogram”. Science 352:658–660
Brizio M, Fava P, Astrua C, Cavaliere G, Savoia P (2015) Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur J Dermatol 25:271–272
Calvet CY, Mir LM (2016) The promising alliance of anti-cancer electrochemotherapy with immunotherapy. Cancer Metastasis Rev 35(2):165–177
Calvet CY, Famin D, Andre FM, Mir LM (2014) Electrochemotherapy with bleomycin induces hallmarks of immunogenic cell death in murine colon cancer cells. Oncoimmunology 3, e28131
Cemazar M, Ambrozic Avgustin J, Pavlin D, Sersa G, Poli A, Krhac Levacic A, Tesic N, Lampreht Tratar U, Rak M, Tozon N (2016). Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours. Vet Comp Oncol doi:10.1111/vco.12208
Cutrera J, Torrero M, Shiomitsu K, Mauldin N, Li S (2008) Intratumoral bleomycin and IL-12 electrochemogenetherapy for treating head and neck tumors in dogs. Methods Mol Biol 423:319–325
Dunn GP, Old LJ, Schreiber RD (2004) The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:137–148
Gerlini G, Di Gennaro P, Borgognoni L (2012) Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology 1:1655–1657
Heppt MV, Eigentler TK, Kahler KC, Herbst RA, Goppner D, Gambichler T, Ulrich J, Dippel E, Loquai C, Schell B, Schilling B, Schad SG, Schultz ES, Matheis F, Tietze JK, Berking C (2016) Immune checkpoint blockade with concurrent electrochemotherapy in advanced melanoma: a retrospective multicenter analysis. Cancer Immunol Immunother 65:951–959
Herrada AA, Rojas-Colonelli N, Gonzalez-Figueroa P, Roco J, Oyarce C, Ligtenberg MA, Lladser A (2012) Harnessing DNA-induced immune responses for improving cancer vaccines. Hum Vaccin Immunother 8:1682–1693
Hribernik A, Cemazar M, Sersa G, Bosnjak M, Snoj M (2016) Effectiveness of electrochemotherapy after IFN-alpha adjuvant therapy of melanoma patients. Radiol Oncol 50:21–27
Inoue H, Tani K (2014) Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 21:39–49
Kim H, Sin JI (2012) Electroporation driven delivery of both an IL-12 expressing plasmid and cisplatin synergizes to inhibit B16 melanoma tumor growth through an NK cell mediated tumor killing mechanism. Hum Vaccin Immunother 8:1714–1721
Kishida T, Asada H, Itokawa Y, Yasutomi K, Shin-Ya M, Gojo S, Cui FD, Ueda Y, Yamagishi H, Imanishi J, Mazda O (2003) Electrochemo-gene therapy of cancer: intratumoral delivery of interleukin-12 gene and bleomycin synergistically induced therapeutic immunity and suppressed subcutaneous and metastatic melanomas in mice. Mol Ther 8:738–745
Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D (2013) Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 39:4–16
Markelc B, Bellard E, Sersa G, Pelofy S, Teissie J, Coer A, Golzio M, Cemazar M (2012) In vivo molecular imaging and histological analysis of changes induced by electric pulses used for plasmid DNA electrotransfer to the skin: a study in a dorsal window chamber in mice. J Membr Biol 245:545–554
Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, Tesniere A, Zitvogel L, Kroemer G (2011) Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 30:1147–1158
Mlecnik B, Bindea G, Kirilovsky A, Angell HK, Obenauf AC, Tosolini M, Church SE, Maby P, Vasaturo A, Angelova M, Fredriksen T, Mauger S, Waldner M, Berger A, Speicher MR, Pages F, Valge-Archer V, Galon J (2016) The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. Sci Transl Med 8, 327ra26
Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, Camerlingo R, Capone M, Madonna G, Festino L, Caraco C, Di Monta G, Marone U, Di Marzo M, Grimaldi AM, Mori S, Ciliberto G, Ascierto PA (2015) Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 4, e1008842
Nars MS, Kaneno R (2013) Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy. Int J Cancer 132:2471–2478
O’Brien MA, Power DG, Clover AJ, Bird B, Soden DM, Forde PF (2014) Local tumour ablative therapies: opportunities for maximising immune engagement and activation. Biochim Biophys Acta 1846:510–523
Li Q, Virtuoso LP, Anderson CD, Eqilmez NK (2015) Regulatory Rebound in IL-12-Treated Tumors Is Driven by Uncommitted Peripheral Regulatory T Cells. J Immunol 195:1293–1300
Reed SD, Fulmer A, Buckholz J, Zhang B, Cutrera J, Shiomitsu K, Li S (2010) Bleomycin/interleukin-12 electrochemogene therapy for treating naturally occurring spontaneous neoplasms in dogs. Cancer Gene Ther 17:457–464
Roux S, Bernat C, Al-Sakere B, Ghiringhelli F, Opolon P, Carpentier AF, Zitvogel L, Mir LM, Robert C (2008) Tumor destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumor responses. Cancer Immunol Immunother 57:1291–1300
Sersa G, Kotnik V, Cemazar M, Miklavcic D, Kotnik A (1996) Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice – natural resistance and immune responsiveness. Anticancer Drugs 7:785–791
Sersa G, Teissie J, Cemazar M, Signori E, Kamensek U, Marshall G, Miklavcic D (2015) Electrochemotherapy of tumors as in situ vaccination boosted by immunogene electrotransfer. Cancer Immunol Immunother 64:1315–1327
Topalian SL, Drake CG, Pardoll DM (2015) Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27:450–461
Torrero MN, Henk WG, Li S (2006) Regression of high-grade malignancy in mice by bleomycin and interleukin-12 electrochemogenetherapy. Clin Cancer Res 12:257–263
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2016 Springer International Publishing AG
About this entry
Cite this entry
Kamensek, U., Kos, S., Sersa, G. (2016). Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy. In: Miklavcic, D. (eds) Handbook of Electroporation. Springer, Cham. https://doi.org/10.1007/978-3-319-26779-1_105-2
Download citation
DOI: https://doi.org/10.1007/978-3-319-26779-1_105-2
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Online ISBN: 978-3-319-26779-1
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences
Publish with us
Chapter history
-
Latest
Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy- Published:
- 19 October 2016
DOI: https://doi.org/10.1007/978-3-319-26779-1_105-2
-
Original
Adjuvant Immunotherapy as a Tool to Boost Effectiveness of Electrochemotherapy- Published:
- 18 August 2016
DOI: https://doi.org/10.1007/978-3-319-26779-1_105-1
